Antiferroptotic activity of non-oxidative dopamine

Biochemical and Biophysical Research Communications

Volumn 480, Issue 4, 2016, Pages 602-607

  Wang, Ding ^a,c   Peng, Yingpeng ^b,c   Xie, Yangchun ^c   Zhou, Borong ^a   Sun, Xiaofang ^a   Kang, Rui ^c   Tang, Daolin ^a,c  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Dopamine; Ferroptosis; Iron; Lipid peroxidation; Receptor

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR D4 PROTEIN; DOPAMINE RECEPTOR D5 PROTEIN; FERROUS ION; GLUTATHIONE; MALONALDEHYDE; MEMBRANE LIPID; PHOSPHOLIPID HYDROPEROXIDE GLUTATHIONE PEROXIDASE; UNCLASSIFIED DRUG; IRON;

ARTICLE; CELL DEATH; EMBRYO; GENE EXPRESSION; HEK293 CELL LINE; HUMAN; HUMAN CELL; IRON METABOLISM; LIPID PEROXIDATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STABILITY; CELL CULTURE; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; OXIDATION REDUCTION REACTION; PHYSIOLOGY;

CELL DEATH; CELL SURVIVAL; CELLS, CULTURED; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IRON; LIPID PEROXIDATION; OXIDATION-REDUCTION;

EID: 84994663353     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2016.10.099     Document Type: Article

References (41)

1. [1] Wise, R.A., Dopamine, learning and motivation. Nat. Rev. Neurosci. 5 (2004), 483–494.
2. [2] Lotharius, J., Brundin, P., Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat. Rev. Neurosci. 3 (2002), 932–942.
3. [3] Tarazi, F.I., Neuropharmacology of dopamine receptors:: implications in neuropsychiatric diseases. J. Sci. Res. Med. Sci. 3 (2001), 93–104.
4. [4] Basu, S., Dasgupta, P.S., Dopamine, a neurotransmitter, influences the immune system. J. Neuroimmunol. 102 (2000), 113–124.
5. [5] Torres-Rosas, R., Yehia, G., Pena, G., Mishra, P., del Rocio Thompson-Bonilla, M., Moreno-Eutimio, M.A., Arriaga-Pizano, L.A., Isibasi, A., Ulloa, L., Dopamine mediates vagal modulation of the immune system by electroacupuncture. Nat. Med. 20 (2014), 291–295.
6. [6] Yan, Y., Jiang, W., Liu, L., Wang, X., Ding, C., Tian, Z., Zhou, R., Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome. Cell 160 (2015), 62–73.
7. [7] Beaulieu, J.M., Espinoza, S., Gainetdinov, R.R., Dopamine receptors - IUPHAR review 13. Br. J. Pharmacol. 172 (2015), 1–23.
8. [8] An, J.J., Cho, S.R., Jeong, D.W., Park, K.W., Ahn, Y.S., Baik, J.H., Anti-proliferative effects and cell death mediated by two isoforms of dopamine D2 receptors in pituitary tumor cells. Mol. Cell Endocrinol. 206 (2003), 49–62.
9. [9] Lemmer, K., Ahnert-Hilger, G., Hopfner, M., Hoegerle, S., Faiss, S., Grabowski, P., Jockers-Scherubl, M., Riecken, E.O., Zeitz, M., Scherubl, H., Expression of dopamine receptors and transporter in neuroendocrine gastrointestinal tumor cells. Life Sci. 71 (2002), 667–678.
10. [10] Stokes, A.H., Hastings, T.G., Vrana, K.E., Cytotoxic and genotoxic potential of dopamine. J. Neurosci. Res. 55 (1999), 659–665.
11. [11] Hare, D.J., Double, K.L., Iron and dopamine: a toxic couple. Brain 139 (2016), 1026–1035.
12. [12] Dixon, S.J., Lemberg, K.M., Lamprecht, M.R., Skouta, R., Zaitsev, E.M., Gleason, C.E., Patel, D.N., Bauer, A.J., Cantley, A.M., Yang, W.S., Morrison, B. 3rd, Stockwell, B.R., Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149 (2012), 1060–1072.
13. [13] Skouta, R., Dixon, S.J., Wang, J., Dunn, D.E., Orman, M., Shimada, K., Rosenberg, P.A., Lo, D.C., Weinberg, J.M., Linkermann, A., Stockwell, B.R., Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J. Am. Chem. Soc. 136 (2014), 4551–4556.
14. [14] Yang, W.S., SriRamaratnam, R., Welsch, M.E., Shimada, K., Skouta, R., Viswanathan, V.S., Cheah, J.H., Clemons, P.A., Shamji, A.F., Clish, C.B., Brown, L.M., Girotti, A.W., Cornish, V.W., Schreiber, S.L., Stockwell, B.R., Regulation of ferroptotic cancer cell death by GPX4. Cell 156 (2014), 317–331.
15. [15] Jiang, L., Kon, N., Li, T., Wang, S.J., Su, T., Hibshoosh, H., Baer, R., Gu, W., Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520 (2015), 57–62.
16. [16] Rajagopalan, M.S., Stone, B., Rwigema, J.C., Salimi, U., Epperly, M.W., Goff, J., Franicola, D., Dixon, T., Cao, S., Zhang, X., Buchholz, B.M., Bauer, A.J., Choi, S., Bakkenist, C., Wang, H., Greenberger, J.S., Intraesophageal manganese superoxide dismutase-plasmid liposomes ameliorates novel total-body and thoracic radiation sensitivity of NOS1-/- mice. Radiat. Res. 174 (2010), 297–312.
17. [17] Berhane, H., Epperly, M.W., Goff, J., Kalash, R., Cao, S., Franicola, D., Zhang, X., Shields, D., Houghton, F., Wang, H., Wipf, P., Parmar, K., Greenberger, J.S., Radiologic differences between bone marrow stromal and hematopoietic progenitor cell lines from Fanconi Anemia (Fancd2(-/-)) mice. Radiat. Res. 181 (2014), 76–89.
18. [18] Tang, D., Kang, R., Livesey, K.M., Cheh, C.W., Farkas, A., Loughran, P., Hoppe, G., Bianchi, M.E., Tracey, K.J., Zeh, H.J. 3rd, Lotze, M.T., Endogenous HMGB1 regulates autophagy. J. Cell Biol. 190 (2010), 881–892.
19. [19] Xie, Y., Hou, W., Song, X., Yu, Y., Huang, J., Sun, X., Kang, R., Tang, D., Ferroptosis: process and function. Cell Death Differ. 23 (2016), 369–379.
20. [20] Yang, W.S., Stockwell, B.R., Ferroptosis: death by lipid peroxidation. Trends Cell Biol. 26 (2016), 165–176.
21. [21] Xie, Y., Song, X., Sun, X., Huang, J., Zhong, M., Lotze, M.T., Zeh, H.J. 3rd, Kang, R., Tang, D., Identification of baicalein as a ferroptosis inhibitor by natural product library screening. Biochem. Biophys. Res. Commun. 473 (2016), 775–780.
22. [22] Yu, Y., Xie, Y., Cao, L., Yang, L., Yang, M., Lotze, M.T., Zeh, H.J., Kang, R., Tang, D., The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents. Mol. Cell Oncol., 2, 2015, e1054549.
23. [23] Zhou, Z.D., Yap, B.P., Gung, A.Y., Leong, S.M., Ang, S.T., Lim, T.M., Dopamine-related and caspase-independent apoptosis in dopaminergic neurons induced by overexpression of human wild type or mutant alpha-synuclein. Exp. Cell Res. 312 (2006), 156–170.
24. [24] Martinez-Vicente, M., Talloczy, Z., Kaushik, S., Massey, A.C., Mazzulli, J., Mosharov, E.V., Hodara, R., Fredenburg, R., Wu, D.C., Follenzi, A., Dauer, W., Przedborski, S., Ischiropoulos, H., Lansbury, P.T., Sulzer, D., Cuervo, A.M., Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J. Clin. Invest. 118 (2008), 777–788.
25. [25] Galluzzi, L., Bravo-San Pedro, J.M., Vitale, I., Aaronson, S.A., Abrams, J.M., Adam, D., Alnemri, E.S., Altucci, L., Andrews, D., Annicchiarico-Petruzzelli, M., Baehrecke, E.H., Bazan, N.G., Bertrand, M.J., Bianchi, K., Blagosklonny, M.V., Blomgren, K., Borner, C., Bredesen, D.E., Brenner, C., Campanella, M., Candi, E., Cecconi, F., Chan, F.K., Chandel, N.S., Cheng, E.H., Chipuk, J.E., Cidlowski, J.A., Ciechanover, A., Dawson, T.M., Dawson, V.L., De Laurenzi, V., De Maria, R., Debatin, K.M., Di Daniele, N., Dixit, V.M., Dynlacht, B.D., El-Deiry, W.S., Fimia, G.M., Flavell, R.A., Fulda, S., Garrido, C., Gougeon, M.L., Green, D.R., Gronemeyer, H., Hajnoczky, G., Hardwick, J.M., Hengartner, M.O., Ichijo, H., Joseph, B., Jost, P.J., Kaufmann, T., Kepp, O., Klionsky, D.J., Knight, R.A., Kumar, S., Lemasters, J.J., Levine, B., Linkermann, A., Lipton, S.A., Lockshin, R.A., Lopez-Otin, C., Lugli, E., Madeo, F., Malorni, W., Marine, J.C., Martin, S.J., Martinou, J.C., Medema, J.P., Meier, P., Melino, S., Mizushima, N., Moll, U., Munoz-Pinedo, C., Nunez, G., Oberst, A., Panaretakis, T., Penninger, J.M., Peter, M.E., Piacentini, M., Pinton, P., Prehn, J.H., Puthalakath, H., Rabinovich, G.A., Ravichandran, K.S., Rizzuto, R., Rodrigues, C.M., Rubinsztein, D.C., Rudel, T., Shi, Y., Simon, H.U., Stockwell, B.R., Szabadkai, G., Tait, S.W., Tang, H.L., Tavernarakis, N., Tsujimoto, Y., Vanden Berghe, T., Vandenabeele, P., Villunger, A., Wagner, E.F., et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ. 22 (2015), 58–73.
26. [26] Yang, W.S., Kim, K.J., Gaschler, M.M., Patel, M., Shchepinov, M.S., Stockwell, B.R., Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), E4966–E4975.
27. [27] Yen, G.C., Hsieh, C.L., Antioxidant effects of dopamine and related compounds. Biosci. Biotechnol. Biochem. 61 (1997), 1646–1649.
28. [28] Fleming, R.E., Ponka, P., Iron overload in human disease. N. Engl. J. Med. 366 (2012), 348–359.
29. [29] von Haehling, S., Jankowska, E.A., van Veldhuisen, D.J., Ponikowski, P., Anker, S.D., Iron deficiency and cardiovascular disease. Nat. Rev. Cardiol. 12 (2015), 659–669.
30. [30] Manz, D.H., Blanchette, N.L., Paul, B.T., Torti, F.M., Torti, S.V., Iron and cancer: recent insights. Ann. N. Y. Acad. Sci. 1368 (2016), 149–161.
31. [31] Sanchez Campos, S., Rodriguez Diez, G., Oresti, G.M., Salvador, G.A., Dopaminergic neurons respond to iron-induced oxidative stress by modulating lipid acylation and deacylation cycles. PLoS One, 10, 2015, e0130726.
32. [32] Hou, W., Xie, Y., Song, X., Sun, X., Lotze, M.T., Zeh, H.J. 3rd, Kang, R., Tang, D., Autophagy promotes ferroptosis by degradation of ferritin. Autophagy 12 (2016), 1425–1428.
33. [33] Bose, A., Beal, M.F., Mitochondrial dysfunction in Parkinson's disease. J. Neurochem., 2016.
34. [34] Youle, R.J., Narendra, D.P., Mechanisms of mitophagy. Nat. Rev. Mol. Cell Biol. 12 (2011), 9–14.
35. [35] Horowitz, M.P., Greenamyre, J.T., Mitochondrial iron metabolism and its role in neurodegeneration. J. Alzheimers Dis. 20:Suppl. 2 (2010), S551–S568.
36. [36] Yuan, H., Li, X., Zhang, X., Kang, R., Tang, D., Identification of ACSL4 as a biomarker and contributor of ferroptosis. Biochem. Biophys. Res. Commun. 478 (2016), 1338–1343.
37. [37] Yuan, H., Li, X., Zhang, X., Kang, R., Tang, D., CISD1 inhibits ferroptosis by protection against mitochondrial lipid peroxidation. Biochem. Biophys. Res. Commun. 478 (2016), 838–844.
38. [38] Sun, X., Niu, X., Chen, R., He, W., Chen, D., Kang, R., Tang, D., Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis. Hepatology 64 (2016), 488–500.
39. [39] Sun, X., Ou, Z., Chen, R., Niu, X., Chen, D., Kang, R., Tang, D., Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology 63 (2016), 173–184.
40. [40] Munoz, P., Huenchuguala, S., Paris, I., Segura-Aguilar, J., Dopamine oxidation and autophagy. Park. Dis., 2012, 2012, 920953.
41. [41] Song, X., Xie, Y., Kang, R., Hou, W., Sun, X., Epperly, M.W., Greenberger, J.S., Tang, D., FANCD2 protects against bone marrow injury from ferroptosis. Biochem. Biophys. Res. Commun., 2016, 10.1016/j.bbrc.2016.10.068 [Epub ahead of print].